About Helande Innovations
Helande Innovations is a San Diego medical device company. It is developing Nervida, an implant for chronic pain. The device is designed to renew relief when pain returns. The aim is renewed relief without another invasive procedure. The first focus is people whose chronic back pain comes back after treatment. For physicians, it is meant to be another potential option for recurring pain.
Kabir Gambhir is CEO and co-founder. Michael Vaninetti, MD, an interventional pain physician, is chief medical officer and co-founder. The founding team has experience in medical device development, executive leadership and interventional pain medicine. Helande is an EvoNexus portfolio company in San Diego.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Apr 9, 2025 | Nov 6, 2026 | $50,000fully sold | 1 | $50,000 | DebtRule 506(b) | Form D ↗ |
| Jul 26, 2026 | Nov 5, 2026 | $70,000of $1.0M target | 3 | $23,333 | Securities on exerciseRule 506(b) | Form D ↗ |
| Total, two offerings | $120,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by Helande Innovations
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|
Why Investors Backed Helande Innovations
Helande is developing an implantable chronic-pain therapy. It is starting with recurring back pain after treatment. Its thesis is that patients need renewed relief without the disruption of repeat procedures. The opportunity remains early and unproven.
The problem it targets
Helande focuses on people whose pain returns after treatment. It views repeat procedures as disruptive and sees a need for renewed relief. A less disruptive option could address that gap if it proves effective.
What the product does
Nervida is an implantable therapy for chronic pain. It is meant to deliver renewed relief while reducing disruption from repeated procedures. Helande has not yet established those benefits.
Progress so far
Nervida remains in preclinical development. Research is needed to establish clinical safety and effectiveness. Federal law limits the device to investigational use, and it lacks approval or clearance for commercial sale. Any future approval is uncertain.
We wrote this summary from public statements by Helande Innovations and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Helande Innovations's Form D filed Nov 6, 2026.